Loading...

BIAF BIOAFFINITY TECHNOLOGIES INC Product Launches 8-K Filing

BFFN

BF

BIOAFFINITY TECHNOLOGIES INC

(BIAF)

2025 8-K

Show Summary

Summary

Private Placement Funding

Financial Update

Delisting Warning

New Product Launches

New Product Launches

Other Special Situation

Other Special Situation

Failure to Meet Listing Sta...

Equity Offerings

Financial Statements

Equity Offerings

Financial Results

Cost Savings Plan

Warrant Agreement

CEO Salary Increase

Stockholder Votes

Investor Webinar

Quarterly Results

Securities Offering

Management Change

Stockholder Vote

Warrant Inducement Agreement

Financial Results

Annual Meeting Results

Financial Results

Financial Results

Issuance of Shares and Warr...

Securities Purchase Agreement

Financial Results

Management Incentive Bonus ...

New Director Appointment

Approval for Payment of CyP...

Financial Results

Amendment Filing

Presentations to Investors

Amendment to Warrants and A...

Financial Results

Amendment to Employment Agr...

Annual Meeting Results

Financial Results Press Rel...

Appointment of CFO

Presentation at Symposium

Nasdaq Closing Bell Ceremony

External Links:

On July 23, 2025, bioAffinity Technologies, Inc. announced a new case study highlighting how their CyPath® Lung technology identified a Stage 1A neuroendocrine tumor that was initially misdiagnosed as non-cancerous inflammation after previous tests.

AI Assistant

BIOAFFINITY TECHNOLOGIES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.